Drugs / ASP-001.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06872866 | Apr 2025 → Feb 2026 overdue | erectile dysfunction | Aspargo Labs, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-06-30 | Aspargo Labs, Inc | Results Aspargo Labs Announces Data on First Oral Spray for Erectile Dysfunction, ASP-001, Showing Two Times Faster Absorption Compared to Viagra® Tablets aspargolabs.com ↗
today announced the release of a Phase 1 study demonstrating that ASP-001, an investigative sildenafil oral spray in development for erectile dysfunction (ED), achieves absorption starting within five minutes, twice as fast as traditional sildenafil tablets. |
| 2023-09-05 | Aspargo Labs, Inc | Regulatory Aspargo Laboratories Announces IND Clearance by U.S. FDA, Enabling Launch of Bioequivalence and Food-Effect Studies for Sildenafil Oral Spray aspargolabs.com ↗
We are thrilled to have received IND clearance from the FDA for Sildenafil Oral Spray for the treatment of ED. |
| 2023-08-01 | Aspargo Labs, Inc | Regulatory Aspargo Laboratories, Inc. Announces Filing of Its Investigational New Drug Application For Sildenafil Oral Spray aspargolabs.com ↗
Aspargo Laboratories, Inc. (“Aspargo” or the “Company”), a privately held specialty pharmaceutical company focused on commercializing innovative formulations of leading tablet medications, announced today that it has submitted an Investigational New Drug (IND) application, which has been accepted for review, to the U.S. Food and Drug Administration (FDA) for ASP-001 (Sildenafil Oral Spray) in the treatment of erectile dysfunction. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP-001.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06872866 ↗ |
| Known as | Hezkue Turbo | “100 mg Hezkue Turbo® (ASP-001.1, Sildenafil)” NCT06872866 ↗ |
| Known as | Sildenafil | “100 mg Hezkue Turbo® (ASP-001.1, Sildenafil)” NCT06872866 ↗ |